Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03905057
Other study ID # EspPRP-ED_001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 26, 2018
Est. completion date June 2021

Study information

Verified date April 2019
Source Dornier MedTech Systems
Contact Josep Torremadé, MD, PhD
Phone +34 932607500
Email jtorremade@bellvitgehospital.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study aims to explore the feasibility, safety and effectiveness of two different extracorporeal shock wave therapy (ESWT) protocols for patients receiving nerve-sparing radical prostatectomy (RP).


Description:

This is an open-label, randomized, 2-parallel-arm trial (n=94). All patients will receive (A) sham (n=47) or (B) active ESWT (n=47) twice/week for 6 weeks (12 sessions total). Concurrently, all patients will receive daily tadalafil 5mg for 24 weeks. Patients will then undergo a 4 week washout period without erectogenic aids, and return for a 28-week evaluation. Subsequently, patients requiring further erectogenic aids after 28 weeks will be offered intracavernosal injections (ICI) of prostaglandin E1 (PGE1).

Random assignment will be performed by computer program (eg. randomizer.org), in a design that obtains equal sample size per group.

All patients will be followed for a period of 24 months post-RP. Follow-up protocol includes evaluation of the IIEF, EHS, GAQ, ICI usage and tolerability, stretched flaccid penile length, urinary incontinence, and oncologic status.


Recruitment information / eligibility

Status Recruiting
Enrollment 94
Est. completion date June 2021
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria:

- Men scheduled for robotic bilateral nerve-sparing radical prostatectomy

- Diagnosed with low/intermediate-risk prostate cancer:

- PSA < 20 ng/ml

- Gleason score < 8

- PCa stage =< T2b

- Baseline IIEF-ED 22-30 without erectogenic aids

- No urinary incontinence (no usage of urinary pads)

- Sexually active, in a stable heterosexual relationship

- Able to understand and complete patient questionnaires

- Consent to participate

Exclusion Criteria:

- Anatomical abnormalities in the genitalia or pelvic region

- Post-RP complications that could impact safety or effectiveness of ESWT (eg. hematoma, fistula, unresolved anastomotic leak)

- Incomplete tumor removal (positive surgical margin)

- Tumor upstaging beyond T2b

- Nerve sparing score < 4

- Previous or scheduled treatment with pelvic radiotherapy and/or androgen deprivation therapy

- Untreated hypogonadism (serum total testosterone < 300 mg/dL)

- Anti-coagulant medication, or any blood coagulation disorders (INR > 3)

- Any other condition that would prevent the patient from completing the study, as judged by the principle investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Dornier Aries 2 (with active applicator)
Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
Dornier Aries 2 (with sham applicator)
Sham ESWT - No shockwave administered

Locations

Country Name City State
Spain Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Dornier MedTech Systems Hospital Universitari de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in average Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) between the groups at 28-week follow up EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) 28-week follow up visit
Primary The difference in average Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) between the groups at 24-month follow up EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) 24-month follow up visit
Secondary Proportion of patients achieving Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) of 22-30 in each group The proportion of patients achieving Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) of 22-30 (indicating mild to no erectile dysfunction) in each group. EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction). baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Change in each domain of the full International Index of Erectile Function (IIEF) score Change in each domain of the full International Index of Erectile Function (IIEF) score from baseline and from each follow-up. EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Change in Erection Hardness Score The Erection Hardness Score (EHS) is a single-item Likert scale to assess erectile dysfunction. Male patients have to answer the question "How would you rate the hardness of your erection?". They answer by selecting from the following options: 0 = Penis does not enlarge; 1 = Penis is large, but not hard; 2 = Penis is hard, but not hard enough for penetration; 3 = Penis is hard enough for penetration, but not completely hard; 4 = Penis is completely hard and fully rigid. baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, in-office ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Change in Global Assessment Questionnaire (GAQ) score The Global Assessment Questionnaire (GAQ) is a tool to evaluate the efficacy of the treatment. Patients will be asked and provide scores (on a scale of 1 to 5) for treatment related, with a score of 1 being least favourable and 5 being most favourable. 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Change in stretched flaccid penile length The flaccid penis of each patient will be stretched and measured from the base of the penis to the tip of the glans. baseline, 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Change in degree of incontinence Incontinence will be determined by the number of pads used per day and the time to achieve 0-1 pad will be compared between the groups. First treatment session, 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Oncologic status The oncologic status of each patient will be evaluated determined by the serum prostate specific antigen (PSA) levels. 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Time to recovery of penetration erection hardness without erectogenic aids Penetration erection hardness is having an EHS score of 3-4. The Erection Hardness Score (EHS) is a single-item Likert scale to assess erectile dysfunction. Male patients have to answer the question "How would you rate the hardness of your erection?". They answer by selecting from the following options: 0 = Penis does not enlarge; 1 = Penis is large, but not hard; 2 = Penis is hard, but not hard enough for penetration; 3 = Penis is hard enough for penetration, but not completely hard; 4 = Penis is completely hard and fully rigid. baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, in-office ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
Secondary Tolerability to and reliance on intracavernosal injections for satisfactory erections: Visual Analog Scale for Pain Patients who are unsatisfied with their erectile function at the 28 week visit, will be offered intracavernosal injections (10mg PGE1, 2x/week) for the remaining duration of the study. During each in-office ICI, patients will report pain tolerability (Visual Analog Scale for Pain), and maximum EHS achieved. Patients will be allowed to stop ICI if they report satisfactory erections without any erectogenic aids for 2 weeks. Patients will be allowed to resume ICI if erectile function decreases, and they report unsatisfactory erections with erectogenic aids for 2 weeks. Dates of stopping and/or resuming ICI will be recorded. At the 52 weeks, 18 and 24 months post-RP follow-up sessions, All patients will self-administer ICI of 10mg PGE1 during the visit, and report pain tolerability (Visual Analog Scale for Pain), and maximum EHS achieved. ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP
See also
  Status Clinical Trial Phase
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT05868668 - Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain N/A
Completed NCT03241758 - Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy N/A
Recruiting NCT05558007 - Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients Phase 2
Completed NCT05332340 - Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered Phase 1
Completed NCT04491773 - Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months
Recruiting NCT05650866 - Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction N/A
Not yet recruiting NCT06126874 - Additional Effects of Aerobic and Resistance Exercises to Pelvic Floor Muscle Training After Radical Prostatectomy N/A
Completed NCT05772598 - Validating the 'Sexual Minorities and Prostate Cancer Scale' to Gold Standard Questionnaires
Recruiting NCT05244486 - Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy N/A
Not yet recruiting NCT06458855 - Nerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy N/A
Completed NCT00335634 - Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery N/A
Recruiting NCT03862599 - Low Intensity Shock-wave Therapy (Li-ESWT) in Penile Rehabilitation After Radical Prostatectomy N/A
Active, not recruiting NCT04434352 - Low Intensity Shockwave Therapy for Erectile Dysfunction N/A
Completed NCT04164355 - Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg
Not yet recruiting NCT05960149 - Use of Indocyanine Green in Robotic Prostate Surgeries Phase 4
Terminated NCT01996852 - Improving Erectile Function and Quality of Life After Prostate Cancer Treatment N/A
Recruiting NCT06076850 - Low-Intensity Extracorporeal Shockwave Therapy for Penile Rehabilitation in Post-Radical Prostatectomy Patients N/A
Terminated NCT01770340 - Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Phase 4
Not yet recruiting NCT05578157 - MENDiP: Measurements of Overnight Penile Temperature to Evaluate Nocturnal Erection Detection in Patients With Absence of Erectile Functioning After Robot-assisted Radical Prostatectomy